News - MedTech & Diagnostics
Virtus Health acquires Adora Fertility and three day hospitals

MedTech News: Virtus Health, a leading global Assisted Reproductive Services (ARS) provider, announced its plans to acquire Adora Fertility and three day hospitals from Australian healthcare company, Healius for $45.0 million.
The Adora Businesses are complementary to Virtus’ existing ARS clinics and day hospitals with four ARS clinics across Australia (WA, NSW, QLD, VIC), with Western Australia – a new market for Virtus – and three day hospitals (WA, NSW, VIC).
The Adora clinics have a demonstrated track record of achieving growth and will add meaningful value to the Virtus Health network. The clinics and day hospitals are fitted with a modern fleet of equipment, recently invested to support the ARS services.
Kate Munnings, Group CEO of Virtus Health said “This acquisition supports our ambition to increase consumer choice by offering diverse models of care across new locations. It also takes our day hospital network to ten facilities and represents our entry into WA.”
Healius CEO Malcolm Parmenter said the sale simplifies Healius’ portfolio of businesses and enables its management to concentrate on its core diagnostics and day hospital businesses.
The acquisition is expected to be completed in Q2 FY22, subject to satisfaction of customary conditions.
News - MedTech & Diagnostics
Roche unlocks new horizons for genomic research in Asia Pacific
Roche is advancing its next-generation sequencing (NGS) ambitions in Asia Pacific following the global launch of AXELIOS 1 in June […]
MoreNews - Pharmaceuticals
‘Unexpected and surprising’: Novartis Lp(a) setback raises tough questions for Amgen and Lilly
The failure of Novartis’ lipoprotein(a) [Lp(a)] therapy to translate substantial biomarker reductions into meaningful cardiovascular benefits has been met with […]
MoreNews - MedTech & Diagnostics
More public hospitals turn to same-day hip and knee surgery, but key blind spots persist
Same-day hip and knee replacements to ease surgical waiting lists are being trialled at The Royal Adelaide Hospital (RAH), but […]
MoreNews - Pharmaceuticals
TGA approves oral Wegovy, prompting questions over efficacy and clinical positioning
The Therapeutic Goods Administration (TGA) approval of Novo Nordisk’s oral GLP-1 receptor agonist Wegovy (semaglutide) is introducing a new dimension to […]
More